首页 | 本学科首页   官方微博 | 高级检索  
检索        

肺炎支原体的耐药机制及治疗
引用本文:张涛,王穗琼.肺炎支原体的耐药机制及治疗[J].中华妇幼临床医学杂志,2013(5):596-599.
作者姓名:张涛  王穗琼
作者单位:广州医科大学附属广东省妇女儿童医院儿科,广东510010
基金项目:广东省科技计划项目(2011B031800226)
摘    要:肺炎支原体(MP)为常见的儿童呼吸道感染病原体之一.随着大环内酯类抗菌药物的广泛应用,耐大环内酯抗菌药物菌(MRMP)呈上升趋势,MRMP感染人群已向成年人蔓延.MRMP较敏感菌株导致感染个体的临床症状持续时间长,肺外并发症发病率高.笔者拟就肺炎支原体流行病学、耐药机制及MRMP的治疗,综述如下.

关 键 词:儿童  肺炎支原体  大环内酯类  耐药  治疗

Summarized on Drug Resistance Mechanism and Treatment in Mycoplasma Pneumoniae Infection
ZHANG Tao,WANG Sui-qiong.Summarized on Drug Resistance Mechanism and Treatment in Mycoplasma Pneumoniae Infection[J].Chinese JOurnal of Obstetrics & Gynecology and Pediatrics,2013(5):596-599.
Authors:ZHANG Tao  WANG Sui-qiong
Institution:. Department of Peadiatrics, Guangdong Women and Children Hospital, Guangzhou 510010 ,Guangdong Province ,China.
Abstract:Mycoplasma pneumoniae is one of major pathogens in community acquired respiratory tract in children and adults. But with macrolides abused, the macrolide-resistance Mycoplasma pneumoniae (MRMP) were dramatically grown, and the MRMP infection spreaded from children to adults in recent years. Many studies demonstrated that the clinical symptoms of MRMP infection were longer and extrapulmonary complications incidence rate was higher than the sensitive strain infection. In this paper, epidemiology, mechanism of resistance and drug resistant strainrs treatment of Mycoplasma pneumoniae were summarized by review literatures.
Keywords:child  Mycoplasma pneumoniae  macrolides  drug resistance  therapy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号